Inhibitors of propagation of coagulation (factors VIII, IX and XI): A review of current therapeutic practice

British Journal of Clinical Pharmacology

Volumn 72, Issue 4, 2011, Pages 553-562

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Factor IX; Factor VIII; Factor XI; Haemophilia; Inhibitors; Therapy

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11 INHIBITOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 2A; RECOMBINANT PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTICOAGULANTS; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR IX; FACTOR VIII; FACTOR XI; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 80052628400     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03899.x     Document Type: Review

References (92)

1. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
2. Haya S, Moret A, Cid AR, Cortina V, Casaña P, Cabrera N, Aznar JA. Inhibitors in haemophilia A: current management and open issues. Haemophilia 2007; 13 (Suppl. 5): 52-60.
3. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor VIII, Factor IX Subcommittee. Definitions in hemophilia. Recommendations of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
4. Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395: 14-8.
5. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179-88.
6. Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, Steinberg DM, Rosove MH, O'Connell N, Lee CA, Seligsohn U. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-8.
7. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
8. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
9. Scandella DH. Properties of anti-factor VIII antibodies in hemophilia A patients. Semin Thromb Haemost 2000; 26: 137-42.
10. Spiegel PC, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4k Fab complex: identification of an inhibitory antibody epitome on the surface of factor VIII. Blood 2001; 98: 13-9.
11. Cox-Gill J. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 500-4.
12. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
13. Lee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemost 2006; 32 (Suppl. 2): 10-4.
14. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
15. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and Environment. Semin Thromb Hemost 2009; 35: 723-34.
16. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci MYoung G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8: 1256-65.
17. Katz J. Prevalence of FIX inhibitors among patients with hemophilia B: results of large scale North American survey. Haemophilia 1996; 2: 38-41.
18. Ljung RC. Gene mutations and inhibitor formation in patients with haemophilia B. Acta Haematol 1995; 94 (Suppl. 1): 49-52.
19. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-6.
20. Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia. Semin Thromb Hemost 2000; 26: 205-8.
21. Von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia 2005; 11 (Suppl. 1): 18-23.
22. Gringeri A, Mannucci PM, for the Italian Association of Haemophilia Centers. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
23. Schulman S. Continuous infusion. Haemophilia 2003; 9: 368-75.
24. Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hemost 2003; 29: 77-85.
25. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
26. Ehrlich HJ, Enzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
27. Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost 2010; 36: 485-92.
28. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
29. Knight C, Danø AM, Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther 2009; 26: 68-88.
30. Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F, van Hout B. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 2009; 15: 420-36.
31. Iorio A, Matino D, D'Amico R, Makris M. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010; 8: CD004449.
32. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-800.
33. Lawler P, White B, Pye S, Hermans C, Riddel A, Costello C, Brown S, Lee CA. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8: 145-8.
34. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
35. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
36. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
37. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg-dose rFVIIa vs. standard 90 microg kg-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
38. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe hemophilia: clinical challengers in the absence as well as in the presence of inhibitors. Haemophilia 2008; 14 (Suppl. 3): 196-201.
39. Franchini M, Manzato F, Salvagno GL, Montagnana M, Zaffanello M, Lippi G. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII. Semin Thromb Hemost 2009; 35: 814-9.
40. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
41. Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, Ferran JM, Ljung RC, Novoseven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
42. Santagostino E, Awerswald G, Jimenez-Yuste V, Ljung R, Morfini M, Rocino A. European initiative to prevent joint damage in haemophilia children with inhibitor (ENJOIH)-a prospective study. Haemophlia 2010; 16 (Suppl. 4): 78. (abstract 17P63).
43. Mannucci PM, Palhares de Miranda PA. International survey of attitudes towards secondary prophylaxis with recombinant factor VIIa in haemophilia A patients with inhibitors. Haemophilia 2009; 15: 345-7.
44. Franchini M, Sassi M, Dell'Anna P, Manzato F, Salvagno GL, Montagnana M, Zaffanello M, Targher G, Lippi G. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Hemost 2009; 35: 76-80.
45. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
46. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
47. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
48. Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Defler K, Hörl WH, Knöbl P. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-7.
49. Di Michele D, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl. 1): 1-22.
50. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors. Haemophilia 2003; 9: 436-63.
51. Lenk H. The German Registry of immune tolerance treatment in hemophilia - 1999 update. Haematologica 2000; 10 (Suppl.): 45-7.
52. Mariani G, Kroner B, for the Immune Tolerance Study Group. Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
53. Di Michele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-8.
54. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77 (Suppl. 1): 33-7.
55. Di Michele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.
56. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13 (Suppl. 5): 73-7.
57. DiMichele DM, Goldberg I, Foulkes M, Hay CRM, on behalf of the International Immune Tolerance Study Group. International prospective randomized immune tolerance (ITI) study: preliminary results of therapeutic efficacy and safety [abstract 07S03]. Haemophilia 2010; 16 (Suppl. 4): 29.
58. Salomon O, Zivelin A, Livnat T, Seligsohn U. Inhibitors to factor XI in patients with severe factor XI deficiency. Semin Hematol 2006; 43 (Suppl. 1): S10-2.
59. Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, Zaffanello M, Cruciali M. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008; 14: 903-12.
60. Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996; 9: 331-54.
61. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
62. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80: 55-63.
63. Collins P, Macartney N, Davies B, Lees S, Giddings J, Maier R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124: 86-90.
64. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010; 148: 183-94.
65. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
66. Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol 1999; 104: 909-14.
67. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Cancer 2001; 91: 1067-74.
68. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81: 768-73.
69. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia centre. Semin Thromb Hemost 2009; 35: 760-8.
70. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112: 250-5.
71. Kessler CM. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica 2000; 85 (Suppl. 1): 57-63.
72. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5: 893-900.
73. Mudad R, Kane WH. DDAVP in acquired haemophilia A: case report and review of the literature. Am J Haematol 1993; 43: 295-9.
74. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, Castellano ME, Shima M, St-Louis J. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-75.
75. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-73.
76. Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 3-7.
77. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13: 451-61.
78. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86: 797-804.
79. Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 1971; 37: 381-7.
80. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-7.
81. Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica 2000; 85: 895-6.
82. Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med 1997; 127: 206-9.
83. Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol 1981; 48: 635-42.
84. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
85. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitor. Blood 2002; 100: 3426-8.
86. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63: 47-52.
87. Nemes L, Pitlik E. Ten years experience with immunotolerance induction therapy in acquired hemophilia. Haematologica 2003; 88 (Suppl. 12): 106-10.
88. Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, Vetter H, Brackmann HH. Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287-93.
89. Mannucci PM. Back to the future: a recent history of hemophilia treatment. Haemophilia 2008; 14 (Suppl. 3): 10-8.
90. Astermark J, Santagostino E, Keith Hoots W. Clinical issues in inhibitors. Haemophilia 2010; 16 (Suppl. 5): 54-60.
91. Study NCT 01064284; EUDRACT n. 2009-011186-88SIPPET study (SIPPET study). Available at (last accessed 10 December 2010).
92. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl. 5): 65-8.